Page last updated: 2024-08-21

indazoles and Leukemia, Myeloid

indazoles has been researched along with Leukemia, Myeloid in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bellamy, WT; Beran, M; Bycott, P; Estrov, Z; Giles, FJ; List, AF; O'Brien, SM; Pithavala, Y; Ravandi, F; Reich, SD; Steinfeldt, H; Verstovsek, S; Yee, KW	1
Albert, DH; Bi, C; Chen, CS; Davidsen, SK; Glaser, KB; Han, JH; Lilly, M; Lim, YP; Loh, SL; Pan, M; Tai, YC; Xie, Z; Zhou, J	1

Trials

1 trial(s) available for indazoles and Leukemia, Myeloid

Article	Year
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leukemia research, 2006, Volume: 30, Issue:7 Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Immunohistochemistry; Indazoles; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Placenta Growth Factor; Predictive Value of Tests; Pregnancy Proteins; Prognosis; Proto-Oncogene Proteins c-kit; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2	2006

Article

Year

The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Leukemia research, 2006, Volume: 30, Issue:7

Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Immunohistochemistry; Indazoles; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Placenta Growth Factor; Predictive Value of Tests; Pregnancy Proteins; Prognosis; Proto-Oncogene Proteins c-kit; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2

2006

Other Studies

1 other study(ies) available for indazoles and Leukemia, Myeloid

Article	Year
Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia, 2008, Volume: 22, Issue:1 Topics: Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Proteins; Cytarabine; Down-Regulation; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Gene Expression Profiling; Humans; Indazoles; Leukemia, Myeloid; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Phenylurea Compounds; Proto-Oncogene Proteins c-mos; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Transplantation, Heterologous	2008

Article

Year

Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway.

Leukemia, 2008, Volume: 22, Issue:1

Topics: Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Proteins; Cytarabine; Down-Regulation; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Gene Expression Profiling; Humans; Indazoles; Leukemia, Myeloid; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Phenylurea Compounds; Proto-Oncogene Proteins c-mos; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Transplantation, Heterologous

2008